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Introduction
Major depressive disorder (MDD) is a global health concern and 
is associated with high levels of disability (Prince et al., 2007). 
First-line recommended treatment options for patients with MDD 
include an antidepressant (selective serotonin reuptake inhibitor 
[SSRI], serotonin norepinephrine reuptake inhibitor [SNRI], mir-
tazapine or bupropion) chosen on the basis of anticipated adverse 
events, individual tolerability and patient preference (American 
Psychiatric Association, 2010). However, many patients do not 
experience an adequate response to initial antidepressant treat-
ment (Nemeroff, 2007). For example, in the open-label Sequenced 
Treatment Alternatives to Relieve Depression (STAR*D) study, 
the rate of response to initial treatment with citalopram was 47% 
(Trivedi et al., 2006). Residual symptoms in unresponsive patients 
are associated with a chronic disease course, greater severity of 
illness and a higher risk of relapse (Bech et al., 2010; Judd et al., 
2000; Thase et al., 1992). Strategies for treating patients who 
respond inadequately to first-line treatment include dose optimi-
sation, combination therapy, augmentation or switching to another 
antidepressant (Bauer et al., 2007; Connolly and Thase, 2011).
Extended-release quetiapine fumarate (quetiapine XR) has 
been evaluated in an extensive clinical trial programme for the 
treatment of MDD both as a monotherapy for the acute treatment 
of adult (Bortnick et al., 2011; Cutler et al., 2009; Earley et al. 
2008; Weisler et al., 2009) and elderly patients (Katila et al., 
2013), as maintenance treatment as a monotherapy (Liebowitz 
et al., 2010) and as adjunct therapy to an antidepressant for the 
acute treatment of adult patients (Bauer et al., 2009; El-Khalili 
et al., 2010). As a consequence of these studies, quetiapine XR 
has been approved in Europe (AstraZeneca Pharmaceuticals 
(Ireland) Ltd, 2013), the USA (AstraZeneca Pharmaceuticals LP, 
2013) and several other countries worldwide as an adjunct to 
antidepressant therapy in patients with an inadequate response to 
antidepressants and as monotherapy in a limited number of coun-
tries including Canada and Australia (please consult individual 
labels for each country).
In patients with MDD who have had an inadequate response to 
initial therapy, identification of potential predictors of response for 
subsequent medications may facilitate optimised treatment. The 
growing clinical interest in identifying predictors of response to 
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treatment is reflected by the increasing number of reports on this 
topic in the literature (Friedman et al., 2012; Leuchter et al., 2009; 
Papakostas and Larsen, 2011; Porcelli et al., 2012; Serretti et al., 
2007; Spronk et al., 2011; Steffens et al., 2011; Uher et al., 2012).
The post hoc analyses reported here used pooled data from the 
two adjunct studies of quetiapine XR (D1448C00006 and 
D1448C00007) to examine clinical and demographic character-
istics of patients to identify any potential predictors of response.
Methods
Fully detailed methodologies for the two studies of adjunct que-
tiapine XR in MDD have been reported previously (Bauer et al., 
2009; El-Khalili et al., 2010) and are summarised here.
Study design and treatment
Data were pooled from two similar, 6-week, double-blind, ran-
domised, placebo-controlled studies of quetiapine XR (150 or 
300 mg/day) as adjunct to ongoing antidepressant therapy in 
patients with MDD and an inadequate response to prior antide-
pressant therapy (Studies D1448C00006 [NCT00326105] 
(El-Khalili et al., 2010) and D1448C00007 [NCT00351910] 
(Bauer et al., 2009)). Written informed consent was provided by 
all patients prior to inclusion and the studies were conducted in 
accordance with the Declaration of Helsinki, the International 
Conference on Harmonisation/Good Clinical Practice guidelines 
and applicable regulatory requirements.
Outpatients (aged 18–65 years) were required to have a 
Diagnostic and Statistical Manual of Mental Disorders, 4th 
Edition (DSM-IV) (American Psychiatric Association, 1994) 
diagnosis of MDD (single episode or recurrent; confirmed by 
Mini-International Neuropsychiatric Interview), a Hamilton 
Depression Rating Scale (HAM-D) (Hamilton, 1960) total score ≥20 and a HAM-D Item 1 (depressed mood) score ≥2 at enrol-
ment and randomisation. Eligible patients also had a history of 
inadequate response to an antidepressant during the current epi-
sode of MDD, defined as continuing depressive symptoms fol-
lowing at least minimum effective antidepressant treatment for 
6 weeks (including ≥1 dose increase) according to their respec-
tive labels.
Key exclusion criteria were: a DSM-IV Axis I disorder other 
than MDD within 6 months of enrolment; a DSM-IV Axis II dis-
order that significantly impacted their current psychiatric status; 
a current episode of MDD >12 months or <4 weeks in duration 
prior to enrolment; history of substance or alcohol abuse; evi-
dence of clinically relevant disease; or serious risk of homicide or 
suicide.
Both studies consisted of an enrolment period (≤14 days) and 
a 6-week randomised treatment period. Study D1448C00006 had 
an additional 2-week drug-discontinuation/follow-up period. 
During enrolment, all prohibited medication was discontinued. 
Patients continued to maintain their previous antidepressant ther-
apy at the same dose from enrolment until the end of double-
blind treatment. Permitted antidepressants in these studies were 
amitriptyline, bupropion, citalopram, duloxetine, escitalopram, 
fluoxetine, paroxetine, sertraline or venlafaxine. In both studies, 
patients were randomised (using a computer-based system) to 
receive either quetiapine XR 150 mg/day, quetiapine XR 300 mg/
day or placebo adjunct to ongoing antidepressant treatment in a 
1:1:1 ratio. The dose of quetiapine XR was 50 mg/day on Days 
1–2, 150 mg/day on Days 3–4 and 300 mg/day on Day 5 accord-
ing to randomisation group. Study treatment was administered 
once daily in the evening. Quetiapine XR tablets were identical 
in appearance, smell and taste to their respective placebo tablets. 
Use of mood stabilisers, other than those allowed in the study 
protocol, or other antipsychotics or psychoactive drugs in the 
7 days prior to randomisation was not permitted. No concomitant 
psychotherapy was permitted (other than supportive psychother-
apy) during the study period, unless psychotherapy had been 
ongoing for a minimum of 3 months before randomisation.
The primary efficacy endpoint in both studies was change 
from randomisation to Week 6 in Montgomery Åsberg Depression 
Rating Scale (MADRS) total score. MADRS response (≥50% 
reduction in MADRS total score from randomisation) rate at 
Week 6 was included as a secondary endpoint.
Statistical analysis
The treatment groups included in the present analyses were que-
tiapine XR (both the 150 mg/day and 300 mg/day doses pooled) 
plus antidepressant and placebo plus antidepressant.
All analyses examining potential predictors of response were 
performed post hoc using the pooled modified intent-to-treat 
(MITT) population, defined as all patients assigned to ran-
domised treatment who took the investigational product, had a 
randomisation MADRS assessment and had at least one valid 
MADRS assessment after randomisation. A last observation car-
ried forward (LOCF) approach was used. Descriptive statistics 
were provided for all analyses.
The effects of baseline psychiatric history, demographic and 
disease characteristics (variables analysed are listed in Table 1) 
on efficacy outcomes were evaluated in three sets of patient sub-
groups according to MADRS response/study completion status: 
1) patients categorised as having a reduction in MADRS total 
score at Week 6 of ≥50% (responders) or <50% (non-respond-
ers); 2) patients categorised as having a reduction in MADRS 
total score at Week 6 of ≥75% (responders) or <25% (non-
responders); and 3) patients categorised as having a reduction in 
MADRS total score at Week 6 of ≥50% (responders) or <50% or 
were non-completers (non-responders). This third analysis pro-
vided an alternative approach to the LOCF analysis.
A further analysis evaluated the number and proportion of 
patients in categories of percentage reduction in MADRS total 
score from baseline to Week 6 (<0%, 0–<15%, 15–<30%, 
30–<45%, 45–<60%, 60–<75%, ≥75%) according to the number 
of depressive episodes (0, 1, 2–3, 4–<10, ≥10) both in the previ-
ous year and lifetime.
To evaluate the effect of baseline disease severity on efficacy 
outcomes, the number and proportion of patients in categories of 
percentage reduction in MADRS total score from baseline to 
Week 6 were also analysed according to baseline Clinical Global 
Impressions-Severity (CGI-S) (National Institute of Mental 
Health, 1976) score categories (Mildly, Moderately, Markedly, 
Severely, Amongst the most severely ill).
The effect of baseline MADRS individual item (Items 1–10) 
scores (0–6) on CGI-Improvement (CGI-I) score at Week 6 
(number and proportion of patients in CGI-I score categories of 
‘Very much’, ‘Much’, ‘Minimally’ improved, No change and 
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‘Very much’, ‘Much’, ‘Minimally’ worse at Week 6) was also 
assessed.
Stepwise model selection was used to identify correlations 
between outcome variables of interest (MADRS response, 
MADRS percentage change from baseline and MADRS total 
score) and potential predictors of outcome (gender, age, weight, 
body mass index [BMI], baseline HAM-D total score, baseline 
MADRS score, baseline CGI-S total score, baseline Hamilton 
Anxiety Rating Scale total score, baseline Quality of Life 
Enjoyment and Satisfaction Questionnaire total score, baseline 
Pittsburgh Sleep Quality Index global score, baseline Simpson-
Angus Scale [SAS] total score, Barnes Akathisia Rating Scale 
global assessment score, baseline depressive mood, baseline 
satisfaction/content score, DSM-IV diagnosis [single episode 
or recurrent MDD], number of hospitalisations, family mem-
bers with MDD, ever attempted suicide, hospitalised for a sui-
cide attempt, total number of major depressive episodes in the 
previous year, lifetime total number of depressive episodes, 
treatment with an SSRI as adjunctive treatment, treatment with 
an SNRI as adjunctive treatment, years since first diagnosis of 
MDD, years since first depressive episode, years since onset of 
present depressive episode and 10 baseline MADRS item scores 
[apparent sadness, reported sadness, inner tension, reduced 
sleep, reduced appetite, concentration difficulties, lassitude, 
inability to feel, pessimistic thoughts and suicidal thoughts]).
Model selection was performed on MADRS percentage 
change and MADRS total score at Week 6 using PROC REG 
stepwise, forward and backward selection methods and on 
responders at Week 6 using PROC LOGISTIC stepwise, forward 
and backward selection models. Statistical analyses were per-
formed using SAS® Version 8.2 (Cary, NC, USA).
Results
Patient population
The pooled patient population has been described previously 
(Bauer et al., 2010a). The pooled MITT population comprised 
616 patients in the quetiapine XR plus antidepressant group (both 
doses pooled) and 303 patients in the placebo plus antidepressant 
group.
Efficacy in the overall pooled population
Efficacy results for the pooled population have been reported 
previously (Bauer et al., 2010a); in brief, least squares means 
changes in MADRS total score from randomisation to Week 6 
were –14.5 for quetiapine XR 150 mg/day plus antidepressant, 
–14.8 for quetiapine XR 300 mg/day plus antidepressant and 
–12.0 for placebo plus antidepressant (p < 0.001 vs. placebo for 
both doses). At Week 6, MADRS response (≥50% reduction in 
MADRS total score) rates were 53.7% for quetiapine XR 
150 mg/day plus antidepressant, 58.3% for quetiapine XR 300 
mg/day plus antidepressant and 46.2% for placebo (p = 0.063 and 
p < 0.01 vs. placebo, respectively).
Table 1. Variables of baseline psychiatric history, demographic and disease characteristics investigated in the post hoc analyses of responders and 
non-responders.
Psychiatric history Demographic characteristics Disease characteristics
Years since first depressive episode
Years since first depressive episode group
(<10, ≥10 years)
Depressive episodes over lifetime
Depressive episodes over lifetime group (<4, ≥4)
Depressive episodes over past year
Number of hospitalisations
Number of hospitalisations group (0, ≥1)
Family members with MDD
Number of family members with MDD (0–1, ≥2)
Biological father with MDD
Biological mother with MDD
Number of biological brothers
Number of biological brothers with MDD
Number of biological sisters
Number of biological sisters with MDD
Number of biological children
Number of biological children with MDD
Any suicide attempt
Number of suicide attempts over lifetime
Hospitalised for suicide attempt
Current or prior exposure (yes, no) to: aripiprazole 
clozapine, olanzapine, quetiapine, risperidone, 
ziprasidone
Gender
Age
Age group (18–39, 40–65 years)
Ethnicity
Region: Australia, Europe, North America, 
South Africa
Weight
Weight group (<78 kg, ≥78 kg)
Waist circumference
BMI
BMI group (<18.5, 18.5–<25, 25–<30,
30–<40, ≥40 kg/m2)
MADRS total score
MADRS severity (total score <28, ≥28)
HAM-D total score
HAM-D severity (total score <28, ≥28)
HAM-D Item 1 score
CGI-S total score
CGI-S severity (total score <5, ≥5)
HAM-A total score
HAM-A severity (total score <19, ≥19)
Q-LES-Q total score
Q-LES-Q severity (total score <45, ≥45)
Q-LES-Q Item 16 score
PSQI global score
PSQI severity (global score <12, ≥12)
BARS total score
SAS total score
DSM-IV diagnosis (single episode or recurrent)
BARS: Barnes Akathisia Rating Scale; BMI: body mass index; CGI-S: Clinical Global Impressions-Severity; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 
4th Edition; HAM-A: Hamilton Anxiety Rating Scale; HAM-D: Hamilton Depression Rating Scale; MADRS: Montgomery Åsberg Depression Rating Scale; MDD: major depres-
sive disorder; PSQI: Pittsburgh Sleep Quality Index; Q-LES-Q: Quality of Life Enjoyment and Satisfaction Questionnaire; SAS: Simpson-Angus Scale.
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Effect of psychiatric history and demographic and disease 
characteristics on efficacy outcomes. Results of the evalua-
tion of the key variables of patients’ psychiatric history and base-
line demographic and disease characteristics in responders and 
non-responders (defined by ≥50% and <50% reduction in 
MADRS total score, respectively) are presented in Table 2 and 
did not reveal any definitive predictive factors for any of the vari-
ables evaluated in either the quetiapine XR plus antidepressant 
group or placebo plus antidepressant group.
Similarly, using the alternative definitions for responders or 
non-responders (≥75%/<25% reduction in MADRS total score, 
respectively), evaluation of the key variables of patients’ psychi-
atric history and baseline demographic and disease characteristics 
did not reveal any definitive predictive factors in either the quetia-
pine XR or placebo groups (Table 3). The inclusion of non-com-
pleters as part of the non-responder group as an alternative to the 
LOCF approach did not show any major differences between the 
results of the two methods of analysis (Table 4).
In addition, no definitive predictive factors were revealed in 
either of the patient populations through the analyses of reduction in 
MADRS total score by number of depressive episodes in the previ-
ous year and the lifetime number of depressive episodes (Table 5).
Effect of disease severity on efficacy outcomes. There was no 
suggestion that baseline disease severity was a predictive factor in 
either the quetiapine XR or placebo groups, as evaluated by the 
Table 2. Analyses of patients’ baseline psychiatric history, demographic and disease characteristics in responders and non-responders defined using 
the cut-offs of ≥50% and <50% reduction in MADRS total score at Week 6, respectively (LOCF; pooled MITT).
 Respondersa Non-respondersb
Quetiapine XR + AD
(n = 345)
Placebo + AD
(n = 140)
Quetiapine XR + AD 
(n = 271)
Placebo + AD
(n = 163)
Psychiatric history
 Years since first depressive episode, mean 13.1 13.6 12.9 15.4
 Depressive episodes over lifetime, mean 9.5 10.0 9.3 9.5
 Depressive episodes over past year, mean 1.3 1.6 1.7 1.3
 Number of hospitalisations, mean 0.5 0.4 0.5 0.6
Demographic characteristics
Gender, %
 Male 29.6 30.0 27.3 36.2
 Female 70.4 70.0 72.7 63.8
Ethnicity, %
 White 93.0 94.3 96.3 93.9
 Black 4.3 5.0 3.0 5.5
 Asian 0.6 0.7 0 0
 Other 2.0 0 0.7 0.6
Region, %
 Australia 5.8 5.7 3.0 4.3
 Europe 40.3 38.6 44.6 45.4
 North America 48.1 50.0 49.8 49.1
 South Africa 5.8 5.7 2.6 1.2
Disease characteristics
MADRS total score, %
 <28 46.1 40.0 48.7 49.1
 ≥28 53.9 60.0 51.3 50.9
HAM-D total score, %
 <28 81.7 81.4 85.2 84.0
 ≥28 18.3 18.6 14.8 16.0
CGI-S total score, %
 <5 54.5 55.7 52.0 58.9
 ≥5 45.5 44.3 48.0 41.1
HAM-A total score, %
 <19 47.0 48.6 39.9 50.3
 ≥19 53.0 51.4 60.1 49.7
AD: antidepressant; CGI-S: Clinical Global Impressions-Severity; HAM-A: Hamilton Anxiety Rating Scale; HAM-D: Hamilton Depression Rating Scale; LOCF: last observation 
carried forward; MADRS: Montgomery Åsberg Depression Rating Scale; MITT: modified intent-to-treat; XR: extended release.
a≥50% reduction in MADRS total score at Week 6.
b<50% reduction in MADRS total score at Week 6.
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analyses of percentage change from baseline to Week 6 in MADRS 
total score by baseline CGI-S score category (Mildly, Moderately, 
Markedly, Severely, Amongst the most severely ill) (Table 4).
MADRS individual items. The investigation of the effect of 
MADRS individual item scores at baseline on CGI-I category 
score at Week 6 also did not show any clear predictive factors for 
either patient population (data not shown).
Stepwise model selection. Predictive correlations revealed 
using stepwise model selection for MADRS (observed) total 
score and percent change from baseline at Week 6 are shown in 
Table 6. Predictive correlations revealed using stepwise model 
selection for responders (observed) at Week 6 are shown in 
Table 7.
Safety and tolerability
Safety and tolerability outcomes have been reported previously 
for these two studies separately and in a pooled analysis (Bauer 
et al., 2009, 2010a; El-Khalili et al., 2010) and were consistent 
with the known tolerability profile for quetiapine.
Table 3. Analyses of patients’ baseline psychiatric history, demographic and disease characteristics in responders and non-responders defined using 
the cut-offs of ≥75% and <25% reduction in MADRS total score at Week 6, respectively (LOCF; pooled MITTa).
Respondersb Non-respondersc
Quetiapine XR + AD 
(n = 175)
Placebo + AD
(n = 60)
Quetiapine XR + AD
(n = 125)
Placebo + AD
(n = 89)
Psychiatric history
Years since first depressive episode, mean 12.9 13.0 14.6 17.7
Depressive episodes over lifetime, mean 8.8 9.9 10.5 11.1
Depressive episodes over past year, mean 1.5 1.6 1.8 1.4
Number of hospitalisations, mean 0.5 0.2 0.6 0.6
Demographic characteristics
Gender, %
 Male 26.3 26.7 28.8 33.7
 Female 73.7 73.3 71.2 66.3
Ethnicity, %
 White 92.0 93.3 95.2 94.4
 Black 5.7 5.0 4.0 5.6
 Asian 0.6 1.7 0 0
 Other 1.7 0 0.8 0
Region, %
 Australia 7.4 10.0 2.4 5.6
 Europe 35.4 35.0 38.4 43.8
 North America 49.1 48.3 56.0 49.4
 South Africa 8.0 6.7 3.2 1.1
Disease characteristics
MADRS severity, %
 <28 47.4 41.7 46.4 49.4
 ≥28 52.6 58.3 53.6 50.6
HAM-D total score, %
 <28 83.4 76.7 83.2 82.0
 ≥28 16.6 23.3 16.8 18.0
CGI-S total score, %
 <5 54.9 60.0 47.2 50.6
  ≥5 45.1 40.0 52.8 49.4
HAM-A total score, %
 <19 48.0 48.3 40.8 52.8
 ≥19 52.0 51.7 59.2 47.2
AD: antidepressant; CGI-S: Clinical Global Impressions-Severity HAM-A: Hamilton Anxiety Rating Scale; HAM-D: Hamilton Depression Rating Scale; LOCF; last observation 
carried forward; MADRS: Montgomery Åsberg Depression Rating Scale; MITT: modified intent-to-treat; XR: extended release.
a The total pooled MITT population comprised 616 patients in the quetiapine XR + AD group and 303 patients in the placebo group; not all patients were included in the 
responders and non-responders categories (≥75% and <25% reduction in MADRS total score at Week 6, respectively).
b≥75% reduction in MADRS total score at Week 6.
c<25% reduction in MADRS total score at Week 6.
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Discussion
Approximately 50% of patients with MDD do not respond to 
treatment with initial first-line antidepressants (Trivedi et al., 
2006). Also, MDD is associated with substantial morbidity and 
mortality and, thus, the consequences are severe if symptoms of 
MDD remain untreated (due to a lack of response) or patients 
experience residual depressive symptoms (due to partial 
response/lack of remission). Therefore, it would be advantageous 
to be able to predict which treatment would be more likely to 
achieve a favourable outcome in order to optimise treatment for 
each patient.
In this analysis of pooled data from two acute studies of 
adjunct quetiapine XR (150–300 mg/day) in patients with MDD 
and an inadequate response to prior antidepressant treatment, no 
major differences between responders and non-responders with 
regard to psychiatric history and baseline demographic and dis-
ease characteristics were observed. Furthermore, there was no 
suggestion of a predictive association between the number of 
depressive episodes, disease severity at baseline, or baseline 
MADRS item scores and efficacy outcomes (assessed by change 
from randomisation in MADRS total score at Week 6). These 
data showing that baseline severity scores are not predictors of 
efficacy are not unexpected, since quetiapine XR monotherapy 
Table 4. Analyses of patients’ baseline psychiatric history, demographic and disease characteristics using an alternative approach to the LOCF 
method (responders defined as patients with ≥50% reduction in MADRS total score at Week 6; non-responders defined as study non-completers or 
patients with <50% reduction in MADRS total score at Week 6) (pooled MITT).
Respondersa Non-respondersb
Quetiapine XR + AD
(n = 316)
Placebo + AD
(n = 133)
Quetiapine XR + AD
(n = 300)
Placebo + AD
(n = 170)
Psychiatric history
 Years since first depressive episode, mean 12.9 13.9 13.2 15.1
 Depressive episodes over lifetime, mean 7.8 10.3 11.1 9.2
 Depressive episodes over past year, mean 1.3 1.6 1.7 1.3
 Number of hospitalisations, mean 0.5 0.4 0.6 0.6
Demographic characteristics
Gender, %  
 Male 29.4 28.6 27.7 37.1
 Female 70.6 71.4 72.3 62.9
Ethnicity, %  
 White 93.7 94.0 95.3 94.1
 Black 4.1 5.3 3.3 5.3
 Asian 0.3 0.8 0.3 0
 Other 1.9 0 1.0 0.6
Region, %  
 Australia 5.4 6.0 3.7 4.1
 Europe 41.5 37.6 43.0 45.9
 North America 47.2 50.4 50.7 48.8
 South Africa 6.0 6.0 2.7 1.2
Disease characteristics
MADRS total score, %  
 <28 45.3 40.6 49.3 48.2
 ≥28 54.7 59.4 50.7 51.8
HAM-D total score, %  
 <28 82.3 82.0 84.3 83.5
 ≥28 17.7 18.0 15.7 16.5
CGI-S total score, %  
 <5 56.3 56.4 50.3 58.2
 ≥5 43.7 43.6 49.7 41.8
HAM-A total score, %  
 <19 46.2 49.6 41.3 49.4
 ≥19 53.8 50.4 58.7 50.6
AD: antidepressant; CGI-S: Clinical Global Impressions-Severity; HAM-A: Hamilton Anxiety Rating Scale; HAM-D: Hamilton Depression Rating Scale; LOCF; last observation 
carried forward; MADRS: Montgomery Åsberg Depression Rating Scale; MITT: modified intent-to-treat; XR: extended release.
a≥50% reduction in MADRS total score at Week 6.
b<50% reduction in MADRS total score at Week 6.
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Table 5. Number and proportion of patients in categories based on percentage change from baseline to Week 6 in MADRS total score by number of depressive episodes in the last year or over the 
patient’s lifetime and by treatment group (pooled MITT).
Treatment Depressive episodes Total % change from baseline in MADRS total score
 <0% reduction, 
n (%)
0%–<15% 
reduction,  
n (%)
15%–<30% 
reduction,  
n (%)
30%–<45% 
reduction, 
n (%)
45%–<60% 
reduction, 
n (%)
60%–<75% 
reduction, 
n (%)
≥75%  
reduction, 
n (%)
Depressive episodes in the last year
Quetiapine XR + AD (n = 616) 0 162 7 (4.3) 14 (8.6) 15 (9.3) 30 (18.5) 21 (13.0) 31 (19.1) 44 (27.2)
 1 296 9 (3.0) 36 (12.2) 34 (11.5) 41 (13.9) 38 (12.8) 55 (18.6) 83 (28.0)
 2–3 114 6 (5.3) 7 (6.1) 9 (7.9) 22 (19.3) 17 (14.9) 23 (20.2) 30 (26.3)
 4–<10 32 2 (6.3) 3 (9.4) 3 (9.4) 4 (12.5) 1 (3.1) 5 (15.6) 14 (43.8)
 ≥10 12 1 (8.3) 1 (8.3) 2 (16.7) 1 (8.3) 2 (16.7) 1 (8.3) 4 (33.3)
 Total 616 25 (4.1) 61 (9.9) 63 (10.7) 98 (15.9) 79 (12.8) 115 (18.7) 175 (28.4)
Placebo + AD (n = 303) 0 101 8 (7.9) 12 (11.9) 16 (15.8) 16 (15.8) 21 (20.8) 8 (7.9) 20 (19.8)
 1 116 10 (8.6) 22 (19.0) 16 (13.8) 12 (10.3) 23 (19.8) 13 (11.2) 20 (17.2)
 2–3 64 5 (7.8) 6 (9.4) 8 (12.5) 10 (15.6) 7 (10.9) 14 (21.9) 14 (21.9)
 4–<10 15 1 (6.7) 0 0 1 (6.7) 6 (40.0) 3 (20.0) 4 (26.7)
 ≥10 7 2 (28.6) 1 (14.3) 0 1 (14.3) 1 (14.3) 0 2 (28.6)
 Total 303 26 (8.6) 41 (13.5) 40 (13.2) 40 (13.2) 58 (19.1) 38 (12.5) 60 (19.8)
Depressive episodes over the patient’s lifetime
Quetiapine XR + AD (n = 616) Missing 10 1 (10.0) 3 (30.0) 1 (10.0) 2 (20.0) 1 (10.0) 2 (20.0) 0
 0 35 1 (2.9) 3 (8.6) 2 (5.7) 4 (11.4) 8 (22.9) 6 (17.1) 11 (31.4)
 1 60 0 6 (10.0) 7 (11.7) 12 (20.0) 6 (10.0) 16 (26.7) 13 (21.7)
 2–3 178 10 (5.6) 16 (9.0) 21 (11.8) 24 (13.5) 20 (11.2) 28 (15.7) 59 (33.1)
 4–<10 180 4 (2.2) 18 (10.0) 20 (11.1) 35 (19.4) 20 (11.1) 33 (18.3) 50 (27.8)
 ≥10 153 9 (5.9) 15 (9.8) 12 (7.8) 21 (13.7) 24 (15.7) 30 (19.6) 42 (27.5)
 Total 616 25 (4.1) 61 (9.9) 63 (10.2) 98 (15.9) 79 (12.8) 115 (18.7) 175 (28.4)
Placebo + AD (n = 303) Missing 2 0 1 (50.0) 1 (50.0) 0 0 0 0
 0 17 3 (17.6) 2 (11.8) 1 (5.9) 4 (23.5) 3 (17.6) 2 (11.8) 2 (11.8)
 1 27 1 (3.7) 4 (14.8) 3 (11.1) 3 (11.1) 6 (22.2) 3 (11.1) 7 (25.9)
 2–3 87 6 (6.9) 16 (18.4) 9 (10.3) 13 (14.9) 18 (20.7) 12 (13.8) 13 (14.9)
 4–<10 81 7 (8.6) 9 (11.1) 13 (16.0) 10 (12.3) 15 (18.5) 9 (11.1) 18 (22.2)
 ≥10 89 9 (10.1) 9 (10.1) 13 (14.6) 10 (11.2) 16 (18.0) 12 (13.5) 20 (22.5)
 Total 303 26 (8.6) 41 (13.5) 40 (13.2) 40 (13.2) 58 (19.1) 38 (12.5) 60 (19.8)
AD: antidepressant; MADRS: Montgomery Åsberg Depression Rating Scale; MITT: modified intent-to-treat; XR: extended release.
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was shown to be effective for the treatment of MDD across a 
broad range of disease severities (Thase et al., 2013). However, a 
number of correlations between the outcome variables response, 
MADRS change from baseline, and MADRS total score and a 
small number of predictors were identified, although the clinical 
relevance of these relationships is unclear.
To our knowledge, no other studies have investigated predic-
tors of response for atypical antipsychotics as adjunct therapy in 
MDD. However, a limited number of studies have looked at pre-
dictors of remission. In a 6-week, open-label randomised study, 
patients with MDD and an inadequate response to an SSRI or ven-
lafaxine received either quetiapine XR as adjunct to an antide-
pressant, lithium as adjunct to an antidepressant or quetiapine XR 
monotherapy (Bauer et al., 2010b); time variables were predictive 
for symptomatic remission. For example, time since first known 
psychiatric disorder was 3.7 years shorter in patients who achieved 
symptomatic remission compared with non-remitters (p < 0.0001). 
Other time variables that were significant predictors of sympto-
matic remission in this study included time since first known 
depressive episode, time since first diagnosis of MDD, time with 
the present depressive episode, and a number of anxiety and 
physical variables (such as lower supine and standing pulse rate) 
(Bauer et al., 2010b).
In the prospectively randomised COmbining Medications to 
Enhance Depression outcomes (CO-MED) study in outpatients 
with MDD, response rates in patients with more severe MDD 
were similar to those reported in patients with mild MDD, sug-
gesting that severity of disease at baseline is not predictive of 
response (Friedman et al., 2012). However, in a multicentre, ran-
domised controlled trial, factors indicative of more severe and/or 
persistent levels of MDD were found to be predictive of treat-
ment response with duloxetine (Howland et al., 2008). Similarly, 
the Genome Based Therapeutic Drugs for Depression (GENDEP) 
study reported that, for nortriptyline, higher BMI and obesity 
predicted poor response whereas for escitalopram, neither of 
these factors significantly affected response (Uher et al., 2009). 
Taken together, these findings suggest that different predictors of 
response may be specific to different treatments, highlighting the 
importance of investigating predictors of response for each 
therapy.
Although we did not find any predictive value prior to adjunc-
tive treatment with quetiapine XR, it is possible that early 
Table 6. Stepwise model selection results in predicting absolute and percent change in MADRS total score at Week 6.
Parameter Estimated absolute change in MADRS 
total score at Week 6
p value
Treatment with quetiapine XR vs. placebo –3.5 0.0002
Increase of 1 in baseline Q-LES-Q score –0.1 <0.0001
Increase of 1 in baseline CGI-S score +2.5 0.0005
Increase of 1 in baseline number of lifetime suicide attempts +0.6 0.0066
1-year increase in time since first episode of depression +0.1 0.0209
Increase of 1 in baseline reduced sleep score +0.9 0.0231
Increase of 1 in baseline pessimistic thoughts score –0.7 0.1099
 Estimated percentage change in MADRS 
total score at Week 6
 
Treatment with quetiapine XR vs. placebo –14.1 <0.0001
Increase of 1 in baseline Q-LES-Q score –0.5 <0.0001
Increase of 1 in baseline CGI-S score +7.5 0.0057
Increase of 1 in baseline number of lifetime suicide attempts +2.2 0.0057
1-year increase in time since first episode of depression +0.1 0.3072
Increase of 1 in total number of major depressive episodes in the previous year +0.7 0.1743
Increase of 1 in baseline MADRS total score –1.4 <0.0001
CGI-S: Clinical Global Impressions-Severity; MADRS: Montgomery Åsberg Depression Rating Scale; Q-LES-Q: Quality of Life Enjoyment and Satisfaction Questionnaire; XR: 
extended release.
Table 7. Stepwise model selection results in predicting Week 6 responder status.
Parameter Estimated odds ratio 95% CI p value
Responder (≥50% reduction in MADRS total score at Week 6)
Treatment with quetiapine XR vs. placebo 1.8 1.33, 2.50 0.0002
Increase of 1 in baseline Q-LES-Q score 1.0 1.03, 1.05 <0.0001
Increase of 1 in baseline MADRS score 1.1 1.03, 1.09 0.0001
Increase of 1 in BARS score 0.7 0.48, 0.98 0.0364
Years since first diagnosis of depression 1.0 0.97, 1.00 0.2986
BARS: Barnes Akathisia Rating Scale; CI: confidence interval; MADRS: Montgomery Åsberg Depression Rating Scale; Q-LES-Q: Quality of Life Enjoyment and Satisfaction 
Questionnaire; XR: extended release.
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improvement during adjunctive therapy, as reported by Muzina 
et al. (2011), may herald better outcomes. An analysis of pooled 
data from three large, randomised, double-blind, placebo-con-
trolled trials of aripiprazole as adjunct to an antidepressant found ≥20% improvement in MADRS total score at Week 2 to be highly 
predictive of remission at Week 6 (Muzina et al., 2011).
The strengths of the current analyses include the large, multi-
national patient population and the large range of clinical param-
eters investigated. A limitation of these analyses is that the data 
were obtained under randomised clinical trial conditions and so 
the patient population was restricted according to the study pro-
tocol (adhering to strict inclusion and exclusion criteria); there-
fore, any conclusions drawn may not be generalisable beyond the 
specific population studied. In addition, these studies used fixed 
dosing, which is not reflective of clinical practice, and were of 
short (6-week) duration so these findings are applicable only to 
acute therapy. A further potential limitation is that we do not have 
any genetic/biomarker data from the present studies to analyse 
for prediction of treatment response. Although no biomarkers are 
currently suitable for clinical application, brain functional meas-
ures, genetic biomarkers, proteomic measures and metabolomic 
measures are currently being investigated and have demonstrated 
various levels of reliability to predict treatment response in MDD 
(Leuchter et al., 2009; Porcelli et al., 2012; Spronk et al., 2011).
In summary, in these analyses of pooled data from the two 
acute studies of adjunct quetiapine XR (150 and 300 mg/day) in 
patients with MDD and an inadequate response to prior antide-
pressant treatment, no predictive factors of treatment response 
were identified. Furthermore, no major differences between 
responders and non-responders were observed with regard to 
psychiatric history and baseline demographic and disease charac-
teristics, and there was no suggestion of a predictive association 
between baseline CGI-S score, number of depressive episodes or 
MADRS item scores and efficacy outcomes. Therefore, our find-
ings do not support reserving adjunct quetiapine XR therapy for 
a particular clinical subset of patients with MDD and an inade-
quate response to prior antidepressant treatment. Further investi-
gation may be required to fully understand any predictive factors 
for response with adjunct quetiapine XR in MDD.
Acknowledgements
We thank Jane Bryant from Complete Medical Communications, who 
provided medical writing support funded by AstraZeneca. The investiga-
tors who were involved in the studies have been acknowledged previ-
ously (Bauer et al., 2009; El-Khalili et al., 2010).
Declaration of Conflicting Interests
The authors declared the following potential conflicts of interest with 
respect to the research, authorship, and/or publication of this article: 
Michael Bauer has received grant/research support from The Stanley 
Medical Research Institute, NARSAD, Deutsche Forschungsgemeinschaft, 
European Commission (FP7) and the American Foundation for Suicide 
Prevention and Bundesministerium für Bildung und Forschung (BMBF). 
He is or has been in the past a consultant for Alkermes, AstraZeneca, 
Bristol-Myers Squibb Co., Ferrer Internacional, Janssen, Eli Lilly & Co., 
H. Lundbeck A/S, Otsuka, Servier and Takeda, and has received speaker 
honoraria from AstraZeneca, Bristol-Myers Squibb Co., GlaxoSmithKline, 
Eli Lilly & Co., H. Lundbeck A/S, Otsuka and Pfizer.
Michael Thase has been an advisor/consultant and/or served on a speak-
ers’ bureau and/or received grant support from Agency for Healthcare 
Research and Quality, Alkermes, AstraZeneca, Bristol-Myers Squibb 
Co., Eli Lilly & Co., Dey Pharma, L.P., Forest, Gerson Lehman Group, 
GlaxoSmithKline, Guidepoint Global, H. Lundbeck A/S, MedAvante., 
Merck and Co., National Institute of Mental Health, Neuronetics, 
Novartis, Otsuka, Ortho-McNeil Pharmaceuticals, Pamlab, L.L.C., 
Pfizer, PGx Health, Sepracor, Shire US, Supernus Pharmaceuticals, 
Takeda and Transcept Pharmaceuticals.
Sherry Liu is an employee of AstraZeneca.
Willie Earley and Hans Eriksson are former employees of AstraZeneca.
Funding
The authors disclosed receipt of the following financial support for the 
research, authorship, and/or publication of this article: The two clinical 
studies and the analyses reported here were supported by AstraZeneca 
Pharmaceuticals.
References
American Psychiatric Association (1994) Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition. Washington, DC: 
American Psychiatric Association. 
American Psychiatric Association (2010) Practice guideline for the 
treatment of patients with major depressive disorder, Third edition 
(2010). Available at: http://psychiatryonline.org/content.aspx?book
id=28&sectionid=1667485 (accessed 3 April 2014).
AstraZeneca Pharmaceuticals (Ireland) Ltd (2013) Seroquel XR – 
Summary of Product Characteristics for Ireland. Available at: 
http://www.medicines.ie/medicine/13032/SPC/ (accessed 3 April 
2014).
AstraZeneca Pharmaceuticals LP (2013) Seroquel XR (quetiapine fuma-
rate) extended release tablets Prescribing Information. Available at: 
http://www1.astrazeneca-us.com/pi/seroquelxr.pdf (accessed 3 April 
2014).
Bauer M, Bschor T, Pfennig A, et al. (2007) World Federation of Soci-
eties of Biological Psychiatry (WFSBP) Guidelines for Biological 
Treatment of Unipolar Depressive Disorders in Primary Care. World 
J Biol Psychiatry 8: 67–104.
Bauer M, El-Khalili N, Datto C, et al. (2010a) A pooled analysis of two 
randomised, placebo-controlled studies of extended release quetiap-
ine fumarate adjunctive to antidepressant therapy in patients with 
major depressive disorder. J Affect Disord 127: 19–30.
Bauer M, Kasper S, Dell’Osso, et al. (2010b) Predictive factors of remis-
sion for treatment-resistant major depressive disorder (MDD) dur-
ing treatment with extended release quetiapine fumarate (quetiapine 
XR). Poster presented at the 10th International Forum on Mood and 
Anxiety Disorders, Vienna, Austria, 17–19 November.
Bauer M, Pretorius HW, Constant EL, et al. (2009) Extended-release 
quetiapine as adjunct to an antidepressant in patients with major 
depressive disorder: Results of a randomized, placebo-controlled, 
double-blind study. J Clin Psychiatry 70: 540–549.
Bech P, Lonn SL, Overo KF, et al. (2010) Relapse prevention and resid-
ual symptoms: A closer analysis of placebo-controlled continuation 
studies with escitalopram in major depressive disorder, generalized 
anxiety disorder, social anxiety disorder, and obsessive-compulsive 
disorder. J Clin Psychiatry 71: 121–129.
Bortnick B, El-Khalili N, Banov M, et al. (2011) Efficacy and tolerability 
of extended release quetiapine fumarate (quetiapine XR) monother-
apy in major depressive disorder: A placebo-controlled, randomized 
study. J Affect Disord 128: 83–94.
Connolly KR and Thase ME (2011) If at first you don’t succeed: A 
review of the evidence for antidepressant augmentation, combina-
tion and switching strategies. Drugs 71: 43–64.
Cutler AJ, Montgomery SA, Feifel D, et al. (2009) Extended release que-
tiapine fumarate monotherapy in major depressive disorder: A pla-
cebo- and duloxetine-controlled study. J Clin Psychiatry 70: 526–539.
574 Journal of Psychopharmacology 29(5)
Earley W, McIntyre A, Wang G, et al. (2008) Double-blind study of the 
efficacy and tolerability of extended release quetiapine fumarate 
(quetiapine XR) monotherapy in patients with major depressive dis-
order (MDD). Int J Psychiatry Clin Pract 12(Suppl 4): 332.
El-Khalili N, Joyce M, Atkinson S, et al. (2010) Extended-release quetiap-
ine fumarate (quetiapine XR) as adjunctive therapy in major depressive 
disorder (MDD) in patients with an inadequate response to ongoing 
antidepressant treatment: A multicentre, randomized, double-blind, 
placebo-controlled study. Int J Neuropsychopharmacol 13: 917–932.
Friedman ES, Davis LL, Zisook S, et al. (2012) Baseline depression 
severity as a predictor of single and combination antidepressant 
treatment outcome: Results from the CO-MED trial. Eur Neuropsy-
chopharmacol 22: 183–199.
Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg 
Psychiatry 23: 56–62.
Howland RH, Wilson MG, Kornstein SG, et al. (2008) Factors predicting 
reduced antidepressant response: Experience with the SNRI duloxetine 
in patients with major depression. Ann Clin Psychiatry 20: 209–218.
Judd LL, Paulus MJ, Schettler PJ, et al. (2000) Does incomplete recovery 
from first lifetime major depressive episode herald a chronic course 
of illness? Am J Psychiatry 157: 1501–1504.
Katila H, Mezhebovsky I, Mulroy A, et al. (2013) Randomized, double-
blind study of the efficacy and tolerability of extended release que-
tiapine fumarate (quetiapine XR) monotherapy in elderly patients 
with major depressive disorder. Am J Geriatr Psychiatry 21: 769–784.
Leuchter AF, Cook IA, Marangell LB, et al. (2009) Comparative effec-
tiveness of biomarkers and clinical indicators for predicting out-
comes of SSRI treatment in Major Depressive Disorder: Results of 
the BRITE-MD study. Psychiatry Res 169: 124–131.
Liebowitz M, Lam RW, Lepola U, et al. (2010) Efficacy and tolerability 
of extended release quetiapine fumarate monotherapy as mainte-
nance treatment of major depressive disorder: A randomized, pla-
cebo-controlled trial. Depress Anxiety 27: 964–976.
Muzina DJ, Chambers JS, Camacho TA, et al. (2011) Adjunctive aripip-
razole for depression: Predictive value of early assessment. Am J 
Manag Care 17: 793–801.
National Institute of Mental Health (1976) CGI Clinical Global Impres-
sions. In: Guy W, Bonato RR (eds) Manual for the ECDEU Assess-
ment Battery. 2. Rev Ed. US Department of Health, Education and 
Welfare, Public Health Service, Alcohol, Drug Abuse and Mental 
Health Administration, NIMH Psychopharmacology Research 
Branch, Division of Extramural Research Programs, Chevy Chase, 
MD. pp.217–222.
Nemeroff CB (2007) Prevalence and management of treatment-resistant 
depression. J Clin Psychiatry 68(Suppl 8): 17–25.
Papakostas GI and Larsen K (2011) Testing anxious depression as a pre-
dictor and moderator of symptom improvement in major depressive 
disorder during treatment with escitalopram. Eur Arch Psychiatry 
Clin Neurosci 261: 147–156.
Porcelli S, Fabbri C, Serretti A (2012) Meta-analysis of serotonin trans-
porter gene promoter polymorphism (5-HTTLPR) association with 
antidepressant efficacy. Eur Neuropsychopharmacol 22: 239–258.
Prince M, Patel V, Saxena S, et al. (2007) No health without mental 
health. Lancet 370: 859–877.
Serretti A, Olgiati P, Liebman MN, et al. (2007) Clinical prediction of 
antidepressant response in mood disorders: Linear multivariate vs. 
neural network models. Psychiatry Res 152: 223–231.
Spronk D, Arns M, Barnett KJ, et al. (2011) An investigation of EEG, 
genetic and cognitive markers of treatment response to antidepres-
sant medication in patients with major depressive disorder: A pilot 
study. J Affect Disord 128: 41–48.
Steffens DC, Nelson JC, Eudicone JM, et al. (2011) Efficacy and safety 
of adjunctive aripiprazole in major depressive disorder in older 
patients: A pooled subpopulation analysis. Int J Geriatr Psychiatry 
26: 564–572.
Thase ME, Montgomery S, Papakostas GI, et al. (2013) Quetiapine XR 
monotherapy in major depressive disorder: A pooled analysis to 
assess the influence of baseline severity on efficacy. Int Clin Psycho-
pharmacol 28: 113–120.
Thase ME, Simons AD, McGeary J, et al. (1992) Relapse after cogni-
tive behavior therapy of depression: Potential implications for longer 
courses of treatment. Am J Psychiatry 149: 1046–1052.
Trivedi MH, Rush AJ, Wisniewski SR, et al. (2006) Evaluation of out-
comes with citalopram for depression using measurement-based 
care in STAR*D: Implications for clinical practice. Am J Psychiatry 
163: 28–40.
Uher R, Mors O, Hauser J, et al. (2009) Body weight as a predictor of 
antidepressant efficacy in the GENDEP project. J Affect Disord 118: 
147–154.
Uher R, Perlis RH, Henigsberg N, et al. (2012) Depression symptom dimen-
sions as predictors of antidepressant treatment outcome: Replicable evi-
dence for interest-activity symptoms. Psychol Med 42: 967–980.
Weisler R, Joyce M, McGill L, et al. (2009) Extended release quetiapine 
fumarate monotherapy for major depressive disorder: Results of a 
double-blind, randomized, placebo-controlled study. CNS Spectr 14: 
299–313.
